Kyverna Files First Autoimmune CAR-T Therapy with US Regulators

Kyverna Therapeutics has had the biologics licence application for mivocabtagene autoleucel accepted by US health authorities, the first regulatory submission for an autologous CAR-T therapy in autoimmunity, seeking approval in stiff person syndrome (SPS). Mivocabtagene autoleucel is a fully human, CD28-co-stimulated CD19 CAR-T designed to deeply deplete B-cells and reset the immune system, with more than 100 patients treated to date and a stable, well-tolerated safety profile supporting the filing.
The clinical signal is meaningful. In the Phase II KYSA-8 study, timed 25-foot walk improved by 46% at week 16 and 49% at month 12, with over a third of patients completing the test within five seconds, while myasthenia gravis patients showed rapid, deep responses on MG-ADL and QMG scores within two weeks.
Kyverna plans a registrational Phase III in myasthenia gravis in 2027, positioning mivocabtagene autoleucel as a potential one-time treatment that could replace chronic immunosuppression.

Daily News
Abbott Pays USD 40mn Upfront for Disco AND-Gated Bispecific Option
2026-11-20
MegaRobo Raises USD 200mn to Scale Physical-World AI Infrastructure
2026-11-20
Novartis Enters ADC Arena With Over USD 2bn OBI Pharma Platform Deal
2026-11-19
Pfizer Licenses Starna's In Vivo CAR-T Platform for Up to USD 2.63bn
2026-11-19
Zelgen's CD3×DLL3 Trispecific Hits Pivotal Endpoint in Relapsed SCLC
2026-11-19
Latest Report
AI- in-BD- Portfolio
Details